Search the Newsreel

Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares

Lynx1 Capital Management LP and Weston Nichols have filed an amended Schedule 13G for iBio, Inc. (IBIO), correcting their reported beneficial ownership to include 2,807,016 shares of common stock issuable upon exercise of Series F warrants. This represents a 5.4% stake in iBio, based …

Vestal Point Capital (IBIO) discloses 4.0M-share iBio position including warrants

Vestal Point Capital, LP and Ryan Wilder have reported an updated beneficial ownership of 4,025,000 shares of iBio, Inc. common stock, which includes 1,425,000 shares issuable from warrants. This holding represents a 7.9% stake in iBio, calculated based on 49,678,561 shares outstanding as of …

Tencent Holdings (BILI) discloses 40M-share beneficial stake in Bilibili

Tencent Holdings Limited has disclosed a beneficial ownership of 40,014,008 Class Z Ordinary Shares in Bilibili Inc., representing 11.8% of the outstanding shares. This stake includes holdings by its subsidiaries Tencent Mobility Limited, Huang River Investment Limited, and China Literature Limited. Tencent Mobility Limited …

Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio

Affinity Asset Advisors, LLC and Michael Cho have disclosed a beneficial ownership of 5,068,882 shares, representing approximately 9.99%, of iBio, Inc.'s common stock. This includes 1,061,001 shares issuable upon the exercise of warrants, all subject to a 9.99% beneficial ownership limitation. The filing, a …

Is Bilibili (BILI) Rewriting Its Investment Story With Creator Monetization Amid Rising AI Costs?

Bilibili is gaining renewed investor attention due to its focus on monetizing its creator ecosystem, despite challenges from tighter Chinese content regulations and increasing AI-related costs. The company's Q1 2026 results showed profitability, with CN¥7,472.04 million in revenue and CN¥209.78 million in net income, …

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants

Sands Capital Life Sciences Pulse Fund II, L.P., along with related entities, has reported a beneficial ownership of 9.3% in Inhibikase Therapeutics, Inc. This stake includes 13,018,965 shares of common stock and substantial warrants for an additional 15.5 million shares, although these warrants are …

Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5

Oppenheimer has reiterated its Buy rating on Inhibikase Therapeutics (IKT.US), maintaining a target price of $5. This indicates continued confidence from the firm in the company's prospects.

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics announced its Q2 2026 financial results, reporting a net loss of $19.6 million and $159.0 million in cash and marketable securities. The company highlighted significant progress in its Phase 3 IMPROVE-PAH study for IKT-001, including regulatory approvals in 26 countries and recent …

Norges Bank (BILI) discloses 23.5M Bilibili shares, a 6.8% ownership stake

Norges Bank, the central bank of Norway, has reported a beneficial ownership stake of 6.8% in Bilibili Inc. (BILI), amounting to 23,468,189 shares. This disclosure was made in a Schedule 13G/A SEC filing. The bank holds sole voting power over all these shares and …

Ibiden (TSE:4062) Is Up 21.7% After Hiking Guidance On AI Server Substrate Demand

Inhibikase Q2 Results: Net Loss Widens to $19.6 Million

Inhibikase Therapeutics reported a Q2 2026 net loss of $19.6 million, or $(0.11) per share, which met analyst estimates but widened from the previous year due to increased R&D spending for its Phase 3 PAH program. The company also raised $50 million through a …

Bilibili Inc (0T3W) Q1 2024 Earnings Report - Results, Call & Slides

Is Bilibili (BILI) Undervalued Or Is Its Recent Bounce Already Priced In?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Bilibili (BILI) has drawn renewed attention after recent share price moves, prompting investors to reassess the stock by looking at its current trading levels, recent …

iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for iBio Inc (IBIO), including its current earnings forecast score, average price target, and analyst ratings. It highlights that the company's expected revenue for the next quarter is 57.14K, and the price target is USD 5.00. Most analysts …

Bilibili Sets August 27 Board Meeting and Q2 2026 Earnings Call

Bilibili Inc. Class Z Revenue Breakdown – GETTEX:71BB

Bilibili Inc. Class Z (GETTEX:71BB) generated €3.76 billion in revenue last year. The majority of this revenue, €1.41 billion, came from its Value-added Services segment, slightly down from €1.48 billion in the previous year. China was the primary geographical contributor, accounting for €3.60 billion …

Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview

Inhibikase Therapeutics, Inc. is projected to report a loss of 11 cents per share in its upcoming earnings. This article serves as an earnings preview, indicating the anticipated financial performance for the company.

iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts

Eight research firms have given iBio, Inc. (NASDAQ:IBIO) a consensus "Buy" rating, with four recommending "Buy" and three "Strong Buy," despite one "Sell" recommendation. The average 12-month price target for IBIO is $5.00, significantly higher than its current trading price of $1.41. The company …

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has received a consensus "Buy" recommendation from nine brokerages, with an average 12-month price target of $5.40. The company's shares recently opened at $2.47, up 2.5%, with a market capitalization of $326.11 million. Several institutional investors, including Goldman Sachs Group …

Análise e Previsão das Ações da Bilibili Inc (BILI)

Bilibili Inc (BILI) Stock News Today

This page provides recent news headlines related to Bilibili Inc (BILI) stock, including its daily performance and market capitalization. The news highlights the movement of Chinese ETFs and ADRs, with Bilibili showing increases on some days. It also touches upon broader trends in Chinese …

iBio Inc (IBIO) Stock News Today

This page provides real-time stock news for iBio Inc (IBIO), including its latest stock price, market capitalization, and performance. It indicates that more news, earnings reports, analyst ratings, and key developments will be updated soon. The current trading data shows IBIO at $1.410, with …

Bilibili (NASDAQ: BILI) plans Q2 2026 results and details share capital

Bilibili Inc. is scheduled to hold a board meeting on August 27, 2026, to approve its unaudited financial results for the second quarter and first half of 2026, which will be announced around 6:00 p.m. Hong Kong Time, followed by an earnings call at …

Bilibili Inc. (BILI) Stock forecasts

An analyst report from Morningstar, dated July 31, 2026, reinforces an advertising-led thesis for Bilibili Inc. (BILI), stating that its shares are undervalued. Bilibili is described as a Chinese online entertainment platform known for its YouTube-like video-sharing service, initially focusing on anime, comics, and …

Projeções de Resultados: Bilibili Inc (BILI) — LPA e Crescimento de Receita

Ibiden Co.,Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Bilibili to report Q2 2026 earnings on August 27 with a live call and webcast.

Bilibili Inc. is scheduled to release its unaudited financial results for the second quarter of 2026 on August 27, prior to the U.S. market open. The company will also host a live earnings call and webcast at 8:00 AM Eastern Time, with registration and …

Bilibili Inc. to Report Second Quarter 2026 Financial Results on Thursday, August 27, 2026

Bilibili Inc. (NASDAQ: BILI and HKEX: 9626) announced it will release its unaudited second-quarter 2026 financial results on Thursday, August 27, 2026, before U.S. markets open. The company will host an earnings conference call at 8:00 AM U.S. Eastern Time on the same day. …

Bilibili sets 8 a.m. ET earnings call for Aug. 27

Bilibili (NASDAQ: BILI; HKEX: 9626) announced it will report its unaudited second-quarter 2026 financial results on Thursday, August 27, 2026, before the U.S. market opens. The management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong Time) …

BanG Dream! Our Notes Global Closed Beta Test Goes Live Today

BILIBILI GAME has launched the global Closed Beta Test (CBT) for BanG Dream! Our Notes, offering players a first look at the rhythm adventure game. The CBT includes the new GEKISO LIVE rhythm mode, the ANON TOKYO boutique, and daily song additions, with exclusive …

Ibiden (TSE:4062) Stock Run Leaves Little Room For Earnings Missteps

iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer

iBio, Inc. (IBIO) has granted its Chief Medical Officer, Molly Carr, 430,000 stock options with an exercise price of $1.40 per share, expiring in 2036. This inducement award, granted outside the company's 2023 Omnibus Incentive Plan, vests 25% after one year, with further quarterly …

iBio appoints Molly Carr as chief medical officer

iBio, Inc. (NASDAQ:IBIO) has appointed Molly Carr, M.D., as its new Chief Medical Officer. Dr. Carr will be responsible for the company's global clinical strategy, medical affairs, and regulatory initiatives, leveraging her 30 years of experience in endocrinology and metabolic disease. She was also …